References
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047–1053 (2004).
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4–14 (2010).
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl. 1), S43–S48 (2006).
- Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for Type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 51(6), 926–940 (2008).
- Laaksonen MA, Knekt P, Rissanen H et al. The relative importance of modifiable potential risk factors of Type 2 diabetes: a meta-analysis of two cohorts. Eur. J. Epidemiol. 25(2), 115–124 (2010).
- Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20(4), 537–544 (1997).
- Tuomilehto J, Lindström J, Eriksson JG et al.; Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343–1350 (2001).
- Abbasi A, Peelen LM, Corpeleijn E et al. Prediction models for risk of developing Type 2 diabetes: systematic literature search and independent external validation study. BMJ 345, e5900 (2012).
- Schulze MB, Hoffmann K, Boeing H et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of Type 2 diabetes. Diabetes Care 30(3), 510–515 (2007).
- Porta M. A Dictionary of Epidemiology. Oxford University Press, New York, NY, USA (2008).
- Montonen J, Drogan D, Joost HG et al. Estimation of the contribution of biomarkers of different metabolic pathways to risk of Type 2 diabetes. Eur. J. Epidemiol. 26(1), 29–38 (2011).
- Schulze MB, Weikert C, Pischon T et al. Use of multiple metabolic and genetic markers to improve the prediction of Type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 32(11), 2116–2119 (2009).
- Lyssenko V, Jonsson A, Almgren P et al. Clinical risk factors, DNA variants, and the development of Type 2 diabetes. N. Engl. J. Med. 359(21), 2220–2232 (2008).
- McKillop AM, Flatt PR. Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine. Diabetes Care 34(12), 2624–2630 (2011).
- Friedrich N. Metabolomics in diabetes research. J. Endocrinol. 215(1), 29–42 (2012).
- Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58(11), 2429–2443 (2009).
- Floegel A, Stefan N, Yu Z et al. Identification of serum metabolites associated with risk of Type 2 diabetes using a targeted metabolomic approach. Diabetes 62(2), 639–648 (2013).
- Breslow N. Design and analysis of case–control studies. Annu. Rev. Public Health 3, 29–54 (1982).
- Floegel A, Drogan D, Wang-Sattler R et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS ONE 6(6), e21103 (2011).